hims & hers fda warning letter compounded semaglutide 2025 cancels plans to sell GLP-1 pill after backlash Hims Semaglutide (2026): FDA Warnings,

otherwise observation Breakthrough bleeding or spotting between periods: Likely mechanism: fluctuating estrogen levels during active weight loss Typical timeline: episodic during weeks 4 to 20 Associated findings: correlates with weeks of accelerated weight loss What it means: uterine lining is responding to unstable estrogen levels Management: usually benign

It's not trying to address hot flashes, joint comfort, inflammation, or the broader range of symptoms that often come with midlife

Because the program is overseen by medical professionals, eligibility is ultimately determined during your clinical assessment

Others have a later peak around weeks 9-10

Advanced Handling Storage optimisation: Use desiccants, log temperatures, avoid fluctuations

In this context, the data controller processes the following personal data: 3.3